News room
TechnoPhage initiates Phase I/IIa study of TP-102 bacteriophage treatment for diabetic foot infections
TechnoPhage announced the beginning of Phase I/IIa study (REVERSE) of TP-102, a phage therapy candidate for the treatment of Diabetic Foot...
Manuel Garrido will attend Phage Futures Congress 2021
TechnoPhage’s Production Specialist, Manuel Garrido, will attend the Phage Futures Virtual Congress 2021. Manuel will participate in the panel...
Technophage once again classified as ‘PME líder’
Technophage has been awarded by IAPMEI (Agency for Competitiveness and Innovation) with the distinction of 'PME líder'. This certification...
TechnoPhage announces U.S. FDA clearance of IND application to initiate clinical trial
U.S. FDA has just cleared the IND application of bacteriophage cocktail TP-102 to initiate Phase I/IIa clinical trial. TP-102 is a cocktail of five...
Technophage among companies with higher investment in R&D
In 2019, Technophage was among the top 100 companies with the highest R&D investment in Portugal. According to the provisional results of...